Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy
© Foerster et al.; licensee BioMed Central Ltd. 2014
Received: 15 January 2014
Accepted: 10 June 2014
Published: 18 June 2014
Type II (papillary serous and clear cell) endometrial carcinoma (EC) is a rare subgroup and is considered to have an unfavorable prognosis. The purpose of this retrospective analysis was to elucidate the meaning of adjuvant radiotherapy (RT) for clinical outcome and to define prognostic factors in these patients (pts).
From 2004-2012 forty-two pts with type II EC underwent surgery followed by adjuvant RT at our department. Median age was 72 years. The majority were early stage carcinomas (FIGO I n = 27 [64.3%], FIGO II n = 4 [9.5%], FIGO III n = 11 [26.2%]. Seven pts (16.7%) received adjuvant chemotherapy (ChT). Pts were treated with external beam radiotherapy (EBRT) and brachytherapy (IVB) boost.
Five-year local recurrence free survival (LRFS), distant metastases free survival (DMFS) and overall survival (OS) were 85.4%, 78%, and 64.5% respectively. LRFS was better with lower pT stage, without lymphangiosis (L0), without haemangiosis (V0) and negative resection margins (R0). DMFS was prolonged in lymph node negatives (N0), L0, V0 and R0. OS was improved in younger pts, N0, L0, V0 and after lymphadenectomy (LNE). Multivariate analysis revealed haemangiosis (V1) as the only independent prognostic factor for OS (p = .014) and DMFS (p = .008). For LRFS pT stage remained as an independent prognostic factor (p = .028).
Adjuvant RT with EBRT/IVB ensures adequate local control in type II EC, but control rates remain lower than in type I EC. A benefit of additional adjuvant ChT could not be demonstrated and a general omission of EBRT cannot be recommended at this point. Lymphovascular infiltration and pT stage might be the best predictive factors for a benefit from combined local and systemic treatment.
Uterine carcinomas with clear cell or papillary serous histology (type II) exhibit different features than endometrioid (type I) carcinomas (EC) . They account for only 10% of all endometrial cancers, but analysis from historical data showed a substantially worse prognosis with frequent recurrences outside the uterus [2–4]. Due to their comparatively low incidence randomized trials on therapy and outcome of patients with theses histologic subtypes are scarce  and the existing retrospective studies have reported varied results regarding the effect of adjuvant radio- and chemotherapy [6, 7]. Another constraint of previously published studies is that they included heterogeneously treated patients over a time frame of more than 20 years [8–10] or that data were extracted from prospective studies which included only a small percentage of type II EC .
This study was planned to investigate the prognosis and survival of women who were treated in recent years with a combined approach of local and systemic therapy.
Screening our patient database we analyzed 410 women who underwent adjuvant radiotherapy (RT) for EC at the Department of Radiation Oncology at the University Hospital Heidelberg in Germany between 2004 and 2012. Among those, 42 cases presented carcinomas with clear cell, papillary serous or mixed histology and thus were included in this retrospective analysis.
All patients were operated with simple hysterectomy, bilateral salpingo-oophorectomy and omental biopsy. In 15 (35.7%) women only pelvic and in 17 (40.5%) pelvic and paraaortic lymph node dissection was performed. RT consisted of external beam radiotherapy (EBRT) in 1.8-2.0 Gy fractions to a cumulative dose of 40-54 Gy (median 45 Gy) and/or HDR intravaginal brachytherapy (IVB) in 5.0 Gy fractions to a cumulative dose of 10-20 Gy (median 10 Gy).
Follow-up was documented and detailed information was gathered on stage, grading, resection status, lymph and blood vessel involvement as well as on prescription of chemotherapy (ChT). For FIGO staging the 2009 classification was used and patients were reclassified if necessary .
Local recurrence free survival (LRFS) was calculated as the time between first diagnosis and occurrence of first local recurrence; with local recurrence being defined as a relapse in the irradiation field. Distant metastases free survival (DMFS) was calculated from day of first diagnosis until day of distant relapse. Disease free survival (DFS) was considered to be the time from first diagnosis until local or distant recurrence. Overall survival (OS) was calculated from date of first diagnosis until death from any cause.
Survival was calculated according to Kaplan and Meier and the log-rank test was used for univariate statistical evaluation. Cox proportional regression model was used for multivariate analysis. A p-value ≤ 0.05 was considered statistically significant.
Statistical analysis was performed with SPSS 22.0 for Windows.
Our research was carried out in compliance with the Helsinki Declaration.
Patients’ and tumor characteristics
Histology N = 42
FIGO stage N = 42
Local tumors spread N = 42
Lymph node status N = 35
Lymphangiosis N = 41
Haemangiosis N = 41
Resection status N = 42
Mean age at diagnosis was 69.9 years (range: 41-89 years). Thirteen women (31%) had clear cell, 20 (47.6%) had papillary serous and 9 (21.4%) had mixed histology carcinomas.
FIGO stages were distributed as follows: stage I 64.3%, stage II 9.5% and stage III 26.2%. None were stage IV. Nine women (25.7%) had positive lymph nodes. Pelvic lymph nodes were resected in 15 patients (35.7%) and in 17 (40.5%) additionally paraaortic lymph nodes were resected. In 19.5% (n = 8) the tumor had infiltrated the lymph and in 17.1% (n = 7) the blood vessels. Positive microscopic resection margins (R1) were found in 14.3% (n = 6) of patients.
Surgery N = 42
Hysterectomy and bilateral salpingo-oophorectomy
Pelvic and paraaortic
Adjuvant chomotherapy N = 42
Adjuvant radiotherapy N = 42
Intravaginal HDR brachytherapy alone
Intravaginal HDR brachytherapy and external beam radiotherapy
Local control was better with lower FIGO stage (p = .031), lower pT stage (p = .001), negative resection margins (p = .037), when lymph or blood vessels were not infiltrated (p = .011; p = .015) and no ChT was applied (p = .048).
Regarding DMFS higher FIGO stage (p = .028), positive lymph nodes (p = .001), positive resection margins (p = .048) as well as lymph and blood vessel infiltration (p = .001; p = .001) were negative prognostic factors.
DFS was prolonged with lower pT stage (p = .009), negative lymph node status (p = .006), no lymph or blood vessel infiltration (p = .001; p = .001), negative resection margins (p = .013) and without ChT (p = .025).
OS was significantly longer in younger patients (p = .028) without lymph node metastases (p = .026), when lymphadenectomy was performed (p = .004) and when neither lymph nor blood vessels were infiltrated by the tumor (p = .016; p = .023).
In recent years efforts have been made to reduce adjuvant treatment to IVB in combination with systemic ChT. While promising results have been published in early stage carcinomas , our results do not support this trend for type II EC in general. Although almost two thirds of the patients in our analysis had stage I carcinomas, survival was generally worse than in patients with type I EC and our results regarding OS and DFS coincide with other reports [4, 5, 8–10, 14–16].
Local control was adequate with 85.4% LRFS after 5-years. This supports previous findings that adjuvant radiotherapy is capable of ensuring a good local control [10, 17]. However, it was far from control rates in women with type I carcinomas; despite that most of our patients (88.1%) underwent combined treatment with EBRT and IVB. Omission of one treatment modality cannot be recommended at this point.
In our analysis only 17% of patients received adjuvant ChT and adding ChT to RT could potentially improve outcome [6, 10, 14, 18, 19]. However, the overall survival benefit from carboplatin/paclitaxel ChT was poor in our analysis and the efficiency of the established taxol/platinum based ChT regimens in type II EC may be questioned. Regardless of the selection bias of treating predominantly stage III patients with adjuvant radiochemotherapy (RChT), which resulted in a significantly worsened outcome after ChT, there was no statistically significant survival difference between the sole RT and the RChT groups. Although numbers are small, this points toward the necessity of new agents and further investigation of molecular targeted therapies such as inhibitors of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) or tyrosin kinase inhibitors (TKI) .
Regarding primary surgical therapy, we found that the conduction of lymphadenectomy was associated with prolonged overall survival in our study, stressing the importance of comprehensive surgical staging [21, 22]. Performance of selective surgical staging, as it is standard for endometrioid uterine carcinoma, cannot be recommended [23, 24].
In our analysis lymphangiosis and haemangiosis were prognostic factors of LRFS, DMFS, DFS and OS in univariate analysis and blood vessel infiltration remained the only independent prognostic factor in multivariate analysis of DMFS, DFS and OS. Lymphovascular invasion has previously been associated with prolonged survival [10, 12, 25–27]. Additionally we found pT stage to be the only independent prognostic factor of prolonged LRFS. Lymphovascular invasion and extend of local tumor spread may therefore be the best predictors of a benefit from combined local and systemic treatment.
Future efforts should be directed towards multi-institutional randomized trials to enable a better understanding of this highly malignant disease’s therapy requirements.
Adjuvant RT with EBRT/IVB ensures adequate local control in type II EC, but control rates remain lower than in type I EC. A benefit of additional adjuvant ChT could not be demonstrated and omission of EBRT, as conducted in early stage type I carcinoma, cannot be recommended at this point. Lymphovascular invasion pT stage might be the best predictive factors for a benefit from combined local and systemic treatment.
We acknowledge financial support by Deutsche Forschungsgemeinschaft and Ruprecht-Karls-Universität Heidelberg within the funding program Open Access Publishing.
- Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control 2009, 16: 46-52.PubMedGoogle Scholar
- Boruta DM, Gehrig PA, Fader AN, Olawaiye AB: Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009, 115: 142-153. 10.1016/j.ygyno.2009.06.011View ArticlePubMedGoogle Scholar
- Greggi S, Mangili G, Scaffa C, Scala F, Losito S, Iodice F, Pisano C, Montoli S, Vigano R, Pirozzi G, Giannarelli D: Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study. Int J Gynecol Cancer 2011, 21: 661-667. 10.1097/IGC.0b013e3182150c89View ArticlePubMedGoogle Scholar
- Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94: 642-646.PubMed CentralPubMedGoogle Scholar
- Fields AL, Einstein MH, Novetsky AP, Gebb J, Goldberg GL: Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2008, 108: 201-206. 10.1016/j.ygyno.2007.09.025View ArticlePubMedGoogle Scholar
- Johnson N, Bryant A, Miles T, Hogberg T, Cornes P: Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011, CD003175.Google Scholar
- Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouelian V, Letarte N, Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lesperance B, Letarte N, Morneau M, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sideris L, Vincent F: Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comite de l'evolution des pratiques en oncologie (CEPO). Gynecol Oncol 2013, 131: 231-240. 10.1016/j.ygyno.2013.07.084View ArticlePubMedGoogle Scholar
- Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG: A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol 2013, 24: 120-127. 10.3802/jgo.2013.24.2.120PubMed CentralView ArticlePubMedGoogle Scholar
- Scarfone G, Secomandi R, Parazzini F, Vigano R, Mangili G, Frigerio L, Villa A, Tateo S, Ricci E, Bolis G: Clear cell and papillary serous endometrial carcinomas: survival in a series of 128 cases. Arch Gynecol Obstet 2013, 287: 351-356. 10.1007/s00404-012-2586-xView ArticlePubMedGoogle Scholar
- Viswanathan AN, Macklin EA, Berkowitz R, Matulonis U: The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol 2011, 123: 542-547. 10.1016/j.ygyno.2011.09.005View ArticlePubMedGoogle Scholar
- Pecorelli S: Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105: 103-104. 10.1016/j.ijgo.2009.02.012View ArticlePubMedGoogle Scholar
- Craighead PS, Sait K, Stuart GC, Arthur K, Nation J, Duggan M, Guo D: Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994. Gynecol Oncol 2000, 77: 248-253. 10.1006/gyno.2000.5746View ArticlePubMedGoogle Scholar
- Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM: Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecol Oncol 2012, 127: 321-325. 10.1016/j.ygyno.2012.07.112View ArticlePubMedGoogle Scholar
- Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villa S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A: Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008, 108: 298-305. 10.1016/j.ygyno.2007.10.037View ArticlePubMedGoogle Scholar
- Yechieli R, Rasool N, Robbins JR, Cogan CM, Elshaikh MA: Adjuvant radiation therapy for patients with type II endometrial carcinoma: impact on tumor recurrence and survival. Int J Gynecol Cancer 2013, 23: 763-768. 10.1097/IGC.0b013e31828b15cbView ArticlePubMedGoogle Scholar
- Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, Steen-Banasik E, Beerman H, van LM: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355: 1404-1411. 10.1016/S0140-6736(00)02139-5View ArticlePubMedGoogle Scholar
- Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2003, 55: 1272-1276. 10.1016/S0360-3016(02)04404-8View ArticlePubMedGoogle Scholar
- Fader AN, Drake RD, O'Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, Gehrig PA, Tuller E, Axtell AE, Zanotti KM: Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009, 115: 2119-2127. 10.1002/cncr.24247View ArticlePubMedGoogle Scholar
- Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G: Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–results from two randomised studies. Eur J Cancer 2010, 46: 2422-2431. 10.1016/j.ejca.2010.06.002PubMed CentralView ArticlePubMedGoogle Scholar
- Thanapprapasr D, Cheewakriangkrai C, Likittanasombut P, Thanapprapasr K, Mutch DG: Targeted endometrial cancer therapy as a future prospect. Womens Health (Lond Engl) 2013, 9: 189-199. 10.2217/whe.13.4View ArticleGoogle Scholar
- Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, Kapp DS, Kapp DS: Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006, 107: 1823-1830. 10.1002/cncr.22185View ArticlePubMedGoogle Scholar
- Fader AN, Boruta D, Olawaiye AB, Gehrig PA: Uterine papillary serous carcinoma: epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010, 22: 21-29. 10.1097/GCO.0b013e328334d8a3View ArticlePubMedGoogle Scholar
- Bristow RE, Asrari F, Trimble EL, Montz FJ: Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease. Gynecol Oncol 2001, 81: 279-286. 10.1006/gyno.2001.6159View ArticlePubMedGoogle Scholar
- del Carmen MG, Birrer M, Schorge JO: Uterine papillary serous cancer: a review of the literature. Gynecol Oncol 2012, 127: 651-661. 10.1016/j.ygyno.2012.09.012View ArticlePubMedGoogle Scholar
- Vance S, Yechieli R, Cogan C, Hanna R, Munkarah A, Elshaikh MA: The prognostic significance of age in surgically staged patients with Type II endometrial carcinoma. Gynecol Oncol 2012, 126: 16-19. 10.1016/j.ygyno.2012.04.011View ArticlePubMedGoogle Scholar
- Weber SK, Sauerwald A, Polcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G, Rudlowski C: Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer 2012, 22: 1442-1448. 10.1097/IGC.0b013e318269139bView ArticlePubMedGoogle Scholar
- Weinberg LE, Kunos CA, Zanotti KM: Lymphovascular Space Invasion (LVSI) Is an Isolated Poor Prognostic Factor for Recurrence and Survival Among Women With Intermediate- to High-Risk Early-Stage Endometrioid Endometrial Cancer. Int J Gynecol Cancer 2013, 23: 1438-1445. 10.1097/IGC.0b013e3182a16c93View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.